South African drugmaker Aspen Pharmacare said on Wednesday it is in talks with a potential partner in Europe after announcing in March a strategic review of its European and domestic commercial pharmaceuticals businesses. Without giving details, in March, Aspen said under the first phase of the review it would split its South African commercial pharmaceuticals business into two divisions to sharpen its focus. Read: Aspen to split SA commercial pharmaceutical business On Wednesday it advised shareholders in a brief statement to exercise caution when dealing in the companyâ€™s shares.